Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 14/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 14/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 14/20 | 0.40 |
| ▸ | GABRP | O00591 | 11/20 | 0.40 |
| ▸ | GABRD | O14764 | 11/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 11/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 11/20 | 0.40 |
| ▸ | GABRE | P78334 | 11/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 11/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 11/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 11/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 11/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217113 | 0.91 | GABRB3 (0.40) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL13892510 | 0.91 | GABRB3 (0.46) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL27602 | 0.90 | GABRB3 (0.39) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL16118103 | 0.90 | GABRB3 (0.41) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL5213914 | 0.82 | GABRP (0.39) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL5219374 | 0.82 | GABRB3 (0.39) | GABRB3GABRA2GABRB2GABRPGABRD | |
| Pyriprole SCHEMBL19032727 | 0.81 | GABRP (0.35) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL4855148 | 0.81 | GABRP (0.41) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL14208660 | 0.79 | GABRP (0.39) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL678537 | 0.79 | VNN1 (0.31) | VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1197492-B1 | PYRAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, AND PESTICIDES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | NIHON NOHYAKU CO LTD (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6849633-B2 | Pyrazole derivative, production process thereof, and pest control agent containing the same as active ingredient | NIHON NOHYAKU CO., LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20030060471-A1 | Pyrazle derivative, production process thereof, and pest control agent containing the same as ative ingredient | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1197492-A1 | PYRAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, AND PESTICIDES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060471-A1 | Pyrazle derivative, production process thereof, and pest control agent containing the same as ative ingredient | ATIC, CYP4X1, AGPS | GABRB3 2372/4885GABRA2 2690/4885GABRB2 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.